|
| A systematic review of the efficacy and safety of Suxiao Jiuxin Pill in the treatment of acute coronary syndrome |
| Hits 970 Download times 598 Received:February 10, 2021 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2021.05.14 |
| Key Words
Suxiao Jiuxin Pill;acute coronary syndrome;incidence of clinical endpoint events;randomized controlled trial;systematic review;Meta-analysis |
| Author Name | Affiliation | E-mail | | LIN Quan | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
Graduate School of China Academy of Chinese Medical Sciences, Beijing 100700, China | | | XU Fengqin | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China | | | MA Xiaojuan | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China | | | ZHANG Miao | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
Graduate School of China Academy of Chinese Medical Sciences, Beijing 100700, China | | | LI Dandan | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
Graduate School of China Academy of Chinese Medical Sciences, Beijing 100700, China | | | YIN Huijun | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China | huijunyin@yeah.net。 |
|
| Abstract
|
| [Objective] To systematically evaluate the efficacy and safety of Suxiao Jiuxin Pill in the treatment of acute coronary syndrome.[Methods] The MEDLINE,EMbase,Cochrane Library,CNKI,VIP and WanFang Data were searched by computer. The randomized controlled trial (RCT) of Suxiao Jiuxin Pill combined with conventional Western medicine (treatment group) and simple conventional Western medicine (control group) in the treatment of acute coronary syndrome was included. The search time was from January 1,2009 to July 15,2019. Two evaluators independently screened the literature,extracted the data and evaluated the bias risk included in the study,and then used RevMan 5.3 software for Meta-analysis.[Results] Eleven RCTs were finally included,with a total of 1 296 patients with acute coronary syndrome. Meta-analysis showed that the incidence of clinical endpoint events in the treatment group[RR=0.29,95%CI (0.17,0.51),P<0.000 1] was significantly lower than that in the control group,and the total clinical effective rate[RR=1.19,95%CI(1.12,1.26),P<0.000 01] and electrocardiogram curative effect[RR=1.29,95%CI(1.14,1.46),P<0.000 1] were significantly higher than those of the control group,and the difference was statistically significant. There was no significant difference in CRP[SMD=-0.55,95%CI(-1.09,-0.01),P=0.05] and incidence of adverse reactions[RR=1.68,95%CI(0.09,30.38),P=0.73] between two groups.[Conclusion] The current evidence shows that Suxiao Jiuxin Pill combined with conventional western medicine can effectively alleviate the clinical symptoms of patients with acute coronary syndrome,improve the efficacy of electrocardiogram and reduce the incidence of clinical endpoint events,and it is safe. Limited by the quality and quantity of the included studies,the above conclusions still need to be verified by more high-quality randomized controlled trials. |
|
|
|
|
|
|
|
